TQB6411 not checked

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1/2 trial completes
Trials
3 active
3 in total
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“TQB6411 Injection is an antibody-drug conjugate (ADC) targeting Epidermal Growth Factor Receptor (EGFR)/c-Met.”In the company’s words, NCT07367516 on ClinicalTrials.gov
Tested for
Esophageal Cancer, Advanced Lung Cancer, Advanced Malignant Tumors
Main trialPhase 1/2
“The Phase Ib stage of this study primarily aims to evaluate the tolerance and safety of TQB6411 Injection in participants with recurrent or metastatic Esophageal cancer who have previously failed treatment with PD-1/PD-L1 monoclonal antibodies combined with platinum-based chemotherapy. The Phase II stage primarily aims to evaluate the efficacy of TQB6411 Injection in this same participants population.”In the company’s words, NCT07367516 on ClinicalTrials.gov

Other drugs for Esophageal Cancer

All 138 drugs for Esophageal Cancer

Coming up3

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials3

TrialPhaseCompletesWhat it tests
Phase 1/2Recruiting Feb 2027 Clinical Trial Evaluating TQB6411 Injection in Participant s With Esophageal Cancer
Phase 1/2Recruiting Dec 2028 A Clinical Trial on the Efficacy and Safety of TQB6411 for Injection
Phase 1Recruiting Dec 2027 A Clinical Trial Evaluating Injection of TQB6411 in Subjects With Advanced Malignant Tumors
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow TQB6411

Following is part of Solo: you see every change to TQB6411 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in